GlassScriptPhysician profile
Kimberly Jacobs
NPI 1619327285
$1,388.86
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $783 · 2022: $449 · 2023: $86.82 · 2024: $69.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $156.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $250.60 | 2021-2023 | Mounjaro |
| Abbvie INC. | $205.09 | 2021-2023 | |
| Abbott Laboratories | $109.18 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $84.80 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $73.45 | 2021 | |
| Pfizer INC. | $68.31 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.00 | 2022-2023 | Synjardy, Jardiance, Tradjenta |
| Amgen INC. | $60.11 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $56.42 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.63 | 2021-2022 | |
| Glaxosmithkline, LLC. | $53.84 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $48.45 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.38 | 2021-2022 | |
| Dexcom, INC. | $40.88 | 2021-2023 | Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $26.11 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $20.51 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.61 | 2022 | |
| Sanofi Pasteur INC. | $18.04 | 2021 | |
| Sunovion Pharmaceuticals INC. | $18.02 | 2021 | |
| Nevro Corp. | $17.76 | 2021 | |
| Esperion Therapeutics, INC. | $17.19 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.23 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.98 | 2021 | |
| Amarin Pharma, INC. | $12.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Jacobs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.